Designed to reduce biologics development time by several months in comparison with traditional manufacturing platforms, SwiftScale's platform leverages synthetic biology techniques and unique strains to produce high yields of therapeutics in their physiological and functional forms at large scale, according to the firm. SwiftScale said that it's in the process of reaching a production capacity of 100,000 doses per month under good manufacturing practices specifications.

FDA researchers explore vaccine responses to SARS-CoV-2 antigens
Different proteins associated with SARS-CoV-2, the virus that causes COVID-19, generate unique immune responses when given to rabbits as immunizations,...

Lilly begins trial for 2nd COVID-19 antibody therapy
Eli Lilly and its partner Junshi Biosciences of Shanghai, China, have begun a phase I clinical trial for Eli Lilly's second COVID-19 antibody therapy.

AbbVie licenses antibody technology for COVID-19
AbbVie, Harbour BioMed, Utrecht University, and Erasmus Medical Center announced that they have entered into a collaboration to develop a novel antibody...

ImmunoPrecise, NIH, Integrated Biotherapeutics test antibodies for COVID-19
ImmunoPrecise Antibodies announced that it is collaborating with the National Institute of Diabetes and Digestive and Kidney Diseases at the National...

Researchers investigate how a potent mAb blocks SARS-CoV-2
Based on previous research that explored therapies against SARS-CoV, a new report has identified a fully human monoclonal antibody (mAb) that prevents...